Cancer Research: The Lessons to Learn from COVID-19

Cancer Discov. 2020 Sep;10(9):1263-1266. doi: 10.1158/2159-8290.CD-20-0823. Epub 2020 Jul 15.

Abstract

The COVID-19 pandemic has caused widespread disruption of cancer clinical trials due to the restrictions on nonessential services and the reallocation of resources, and at the same time the urgent global effort toward discovering therapies that treat or prevent COVID-19 infection has led to shortening of traditional regulatory timelines. This experience should stimulate similar urgency in the way future cancer research is conducted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Betacoronavirus / isolation & purification
  • Biomedical Research / economics
  • Biomedical Research / organization & administration
  • Biomedical Research / standards
  • Biomedical Research / trends*
  • COVID-19
  • Clinical Trials as Topic / economics
  • Clinical Trials as Topic / organization & administration*
  • Clinical Trials as Topic / standards
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / therapy*
  • Coronavirus Infections / virology
  • Forecasting
  • Health Care Rationing / organization & administration
  • Health Care Rationing / standards
  • Health Care Rationing / trends
  • Humans
  • Medical Oncology / economics
  • Medical Oncology / organization & administration
  • Medical Oncology / standards
  • Medical Oncology / trends*
  • Neoplasms / therapy*
  • Pandemics
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / therapy*
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Time Factors